The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo
Abstract
Hormonal ablation is the standard treatment for disseminated androgen‐dependent prostate cancer. Although tumor growth is controlled at first, the tumor invariably recurs in the form of castration‐resistant prostate cancer. This study assessed the efficacy of a new therapeutic strategy that combines plumbagin, a naturally occurring naphthoquinone, with androgen ablation.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 19, 2012
- Source ID
- 10.1002/pros.22585
Entities
People
- Adrian Chrastina
- John Welsh
- Parisa Abedinpour
- Per Borgström
- Véronique T. Baron